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Tackle Epithelial-Mesenchymal
Transition With Epigenetic Drugs in
Cancer
Bo Dong1,2, Zhaoping Qiu1,2 and Yadi Wu1,2*
1Department of Pharmacology and Nutritional Sciences, University of Kentucky School of Medicine, Lexington, KY, United States,
2Markey Cancer Center, University of Kentucky School of Medicine, Lexington, KY, United States
Epithelial-mesenchymal Transition (EMT) is a de-differentiation process in which epithelial
cells lose their epithelial properties to acquire mesenchymal features. EMT is essential for
embryogenesis and wound healing but is aberrantly activated in pathological conditions
like fibrosis and cancer. Tumor-associated EMT contributes to cancer cell initiation,
invasion, metastasis, drug resistance and recurrence. This dynamic and reversible
event is governed by EMT-transcription factors (EMT-TFs) with epigenetic complexes.
In this review, we discuss recent advances regarding the mechanisms that modulate EMT
in the context of epigenetic regulation, with emphasis on epigenetic drugs, such as DNA
demethylating reagents, inhibitors of histone modifiers and non-coding RNA medication.
Therapeutic contributions that improve epigenetic regulation of EMT will translate the
clinical manifestation as treating cancer progression more efficiently.
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INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a phenomenon which involves the capacity of cells to
interconvert between cellular states of the epithelial-mesenchymal axis and varying biological
requirements (Bhatia et al., 2017; Yang et al., 2020). During this process, epithelial cells
gradually dissolve cell-cell junctions, rebuild cell-matrix connections and attain mesenchymal
phenotypes such as increased motility and invasiveness (Yuan et al., 2019). The resulting cells
shift back, lose acquired mesenchymal traits and regain epithelial characteristics via mesenchymal-
epithelial transition (MET) (Pei et al., 2019). Intriguingly, this cellular plasticity is very flexible, and
transition in vivo appears to be partially performed; epithelial cells often undergo partial remodeling
and display mixed combination of epithelial and mesenchymal features during EMT (Pastushenko
and Blanpain, 2019). Such cellular conversions and the resultant heterogeneity are believed to equip
cells with pliability to cope with different developmental and pathological occasions (Yang et al.,
2020).
EMT can be activated by a cohort of soluble growth factors, extracellular matrix and micro-
environmental conditions (Dongre andWeinberg, 2019). Outside mediators trigger within epithelial
cells a large number of intracellular cascades, which ultimately refashion expressions of several EMT-
TFs such as Snail/Slug, ZEB1/2 and Twist1/2 (Puisieux et al., 2014). These EMT-TFs cooperate in
varied combinations to initiate EMT programs, orchestrating molecular interactions with regulatory
elements at multiply layers (Lin et al., 2014). EMT programs include downregulation of genes
associated with epithelial maintenance and upregulation of genes required for mesenchymal
characteristics, doing so to confer cellular shift among the epithelial-mesenchymal spectrum
(Pastushenko and Blanpain, 2019). For instance, a notable molecular hallmark of EMT is
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repression of E-cadherin, a transmembrane glycoprotein encoded
by the epithelial marker gene CDH1 and essential for epithelial
cell-cell junctions. Repression of E-cadherin, occasionally caused
by genetic degeneration, can often be achieved through EMT-TFs
binding to the E-cadherin promoter, which then recruit
repressive transcriptional complexes.
Aside from being widely observed during development,
wounding healing and tissue fibrosis, EMT is frequently
associated with cancer progression (Brabletz et al., 2018).
When carcinoma cells progress toward states of high-grade
malignancy, EMT bestows cancerous cells with enhanced
invasiveness that favors their spread through adjacent tissues
and dissemination to distant sites, followed by recovery of
proliferation potential as metastatic growth (Kröger et al.,
2019). Furthermore, cancerous cells actively employing EMT
often display elevated resistance to antitumor drugs and
immunotherapy, and show properties reminiscent of cancer
stem cell, a minority of phenotypically distinct cancer cell
within a tumor mass capable of seeding new tumors (Shibue
and Weinberg, 2017; Wilson et al., 2020). As a result, therapies
that target subpopulations of cancerous cells undergoing EMT
may generate consequential anticancer efficacy (Marcucci et al.,
2016). Nonetheless, the exact role of EMT during cancer
progression is far from clear (Nieto et al., 2016; Stemmler
et al., 2019; Williams et al., 2019).
As our characterization of the EMT pathway expands, it
becomes clear that activation and execution of EMT occurs as
a result of genetic and epigenetic process (Skrypek et al., 2017).
The word “epigenetic” refers to a layer of information existing
beyond genetic data encoded in the genomic DNA sequence
(Greally, 2018). Genomic DNA in eukaryotic cells interacts with
histone proteins and RNA to form the chromatin, which serves as
the crucial platform for epigenetic regulation of gene expression.
Epigenetic regulation largely depends on alteration of chromatin
states through regulators responsible for DNAmethylation, post-
translational modifications (PTMs) of nucleosomal histone tails
and/or non-coding RNA modulation (Wen et al., 2009).
Deregulation of epigenetic modifications constantly contribute
to cellular disorders that lead to malignant transformation. A
variety of epigenetic regulators are considered as critical
requirements that interpret EMT signals passed from
stimulators to transcription factors (Tam and Weinberg,
2013). Here, we outline the modulatory mechanisms of EMT
during cancer progression, focusing on epigenetic regulation and
compounds that target these epigenetic modifiers. An expanding
description of the epigenetic regulations that underlie the
contribution of EMT to cancer progression will provide
momentous insights for “epigendrug” to treat cancer
metastasis and therapeutic resistance.
EPITHELIAL-MESENCHYMAL TRANSITION
AND DNA METHYLATION
DNA methylation involves a covalent attachment of a methyl
group to the cytosine residues at the CpG-rich dinucleotide
sequence (CpG island) through DNA methyltransferases
(DNMTs). It is a stable and reversible process, with
demethylation catalyzed by members of the ten-eleven
translocation methyl cytosine dioxygenase (TET) (Rasmussen
and Helin, 2016). DNA methylation usually modulates gene
expression through the combination of two mechanisms. The
presence of methyl groups within the CpG island can directly
impair the recognition of transcription factors to CG-rich motifs,
thus hinder gene expression. DNA methylation also serves as
epigenetic marks to attract methyl-CpG binding-domain proteins
(MBDs). MBDs interact with transcription factors, which recruit
chromatin remodelers and histone-modifying proteins, thereby
turning DNA methylation into activation or repressive signal
depending on the cellular context. Upon induction of EMT,
hypermethylation of the CDH1 promoter through DNMTs,
which are recruited by EMT-TFs, is constantly observed in a
wide variety of cancer cells. In addition, the expression of EMT-
TFs and other components of EMT regulatory elements are also
regulated by DNA methylation. DNA demethylation promoted
by TET is essential for MET in somatic cell reprogramming (Hu
et al., 2014). The Mbd3/NuRD complex cooperates with TET2
and keeps cancer cells in a highly metastatic mesenchymal state.
Combinatorial interference with their functions leads to MET
and efficient repression of metastasis (Nihan Kilinc et al., 2020).
Decitabine, along with azacytidine, are two DNMT inhibitors
that have displayed promising responses at sub-cytotoxic doses in
myelodysplastic syndrome and are now FDA approved for use in
this disease. Numerous studies indicated that treatment with
decitabine leads to promoter demethylation and reactivates
E-cadherin expression in certain cancer cell lines (Graff et al.,
1995; Yoshiura et al., 1995; Nakayama et al., 2001; Maruya et al.,
2004; Tsutsumida et al., 2004; Ishikawa et al., 2017). Conversely,
other reports revealed conflicting results in which inhibition of
DNMTs by decitabine facilitates the metastasis of cancer cells,
concomitant with induction of pro-invasive genes (Ateeq et al.,
2008; Lee et al., 2016). The first-generation of DNMT inhibitors,
including decitabine, are all nucleoside analogs which incorporate
into replicating DNA; they irreversibly attach with all DNMTs
and induce their degradation. Therefore, treatment with these
inhibitors generally leads to global loss of DNA methylation and
displays broad cellular effects and limited clinical efficacy.
Compared with these drugs, guadecitabine (SGI-110) is a
prodrug of decitabine with improved pharmacologic and
pharmacokinetic effects. It is under clinical investigation, alone
or in combination with other therapies, in a number of solid and
hematopoietic malignancies (Issa et al., 2015; Kantarjian et al.,
2017). Studies show that dynamic changes in the DNA
methylome occur in TGF-β-induced EMT. TGF-β can induce
both expression and activity of DNMT1 and DNMT3A/B.
Treatment with SGI-110 prevents TGF-β-induced EMT in
ovarian cancer cells (Cardenas et al., 2014). Moreover, a
reversible, non-DNA-incorporating DNMT1 inhibitor
GSK3482364 was recently developed with significantly
improved pharmacological properties (Gilmartin et al., 2020).
This new class of DNA inhibitors is orally bioavailable and
displays robust loss of DNA demethylation without the
limitation of off-target effects. Preclinical and clinical
characterization will be needed to determine whether these
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new DNMT1 inhibitors offer advantages over the classical DNA
hypomethylating drugs. On the other hand, because DNMT
inhibitors can reverse the hypermethylated state at the
promoters of epithelial markers such as E-cadherin, they also
induce the activation of pro-metastatic genes. For instance, a
most recent work indicates that DNMT1 can be recruited by a
subunit of the chromatin remodeling complex to the Snail
promoter and suppress its transcription, therefore down-
regulation of DNMT1 could also induce expression of EMT-
TFs (Jiang et al., 2020). Consequently, targeting the DNA
methylation readers like MBDs may provide a suitable
alternative for the next generation of epigenetic therapies, and
several studies have shown promising effects in terms of
developing anticancer therapeutic strategies against the MBDs
(Mahmood and Rabbani, 2019).
EPITHELIAL-MESENCHYMAL TRANSITION
AND HISTONE MODIFICATION
Acetylation
Lysine acetylation of histone tails, one of the most frequently
found PTMs, is catalyzed by a variety of transcriptional co-
activating complexes which contain lysine acetyltransferases
(KATs). Because acetylation masks the positive charge on
lysine residues, thereby weakening DNA-histone association
and relaxing chromatin structure, histone acetylation is often
associated with gene activation. The histone acetyltransferase
adenovirus E1A-associated protein (p300) and CREB binding
protein (CBP) are key transcriptional coactivator essential for a
multitude of cellular processes and implicated in cancer
progression. P300/CBP acetyltrasferases proximal region of the
Slug promoter to enhance metastasis (Xin et al., 2019). In
addition, p300/CBP-associated factor (PCAF)-dependent
acetylation of the transcription factor intestine-specific
homeobox (ISX) promotes its interaction with BRD4 and
translocation of the resulting complex into the nucleus. This
complex binds to promoters of EMT genes, where acetylation of
histone three at lysine 9, 14, and 18 thus initiates transcriptional
activation; these findings indicate that the p300/CBP-ISX-BRD4
axis mediates EMT and regulates tumor initiation and metastasis
(Wang L.-T. et al., 2020).
Recently, several p300/CBP inhibitors have been developed,
including natural products (Balasubramanyam et al., 2004), bi-
substrate analogs (Lys-CoA) (Lau et al., 2000) and the widely
utilized C646 (Bowers et al., 2010; Shrimp et al., 2016). C646
inhibits cell viability and promotes cell apoptosis in different
cancer cells. I-CBP112, a specific and potent acetyl-lysine
competitive protein-protein interaction inhibitor, targets the
p300/CBP bromodomains (Picaud et al., 2015). I-CBP112
impairs aberrant self-renewal of leukemic cells and
synergistically suppresses cell growth with the BET
bromodomain inhibitor JQ as well as doxorubicin.
Interestingly, NEO2734, a novel dual p300/CBP and BET
bromodomain-selective inhibitor, inhibits growth and cancer
progression (Yan et al., 2019; Morrison-Smith et al., 2020).
However, most of these inhibitors lack potency or selectivity.
A-485, a potent, selective and drug-like p300/CBP catalytic
inhibitor, selectively inhibits proliferation across lineage-
specific tumor types (Lasko et al., 2017).
Deacetylation
Histone deacetylation reveals the positive charge of lysine and
permits DNA-histone interaction. Therefore, histone
deacetylation is believed to restrict gene transcription. Similar
to KATs, histone deacetylases (HDACs) often form large
complexes with other epigenetic modifiers to remove acetyl
residue from their targets, serving as transcriptional repressors.
KATs and HDACs together maintain histone acetylation at an
appropriate intensity for proper gene regulation. Disturbing the
balance between acetylation and deacetylation is highly
associated with cancer progression. HDACs, in particular
HDAC1 and HDAC2, are often recruited by EMT-TFs to gene
promoter regions and form protein complexes to deacetylate
histones and silence expression of epithelial gene factors. For
instances, Snail mediates recruitment of the HDAC1/2 that
contain Sin3A or NuRD repressor complexes to inhibit
E-cadherin expression (Fujita et al., 2003; Peinado et al.,
2004). Likewise, Twist1 and ZEB2 interact with the Mi2/
NuRD complex and recruit them to the proximal regions of
the E-cadherin promoter for transcriptional repression
(Verstappen et al., 2008; Fu et al., 2011).
Recently, a number of HDAC inhibitors have been developed.
They are divided into four basic structural classes including short
chain fatty acids, hydroxamic acid–derived compounds,
benzamides and cyclic peptides (Wawruszak et al., 2019).
Among them, four drugs have been approved by the United
States Food and Drug Administration, namely vorinostat,
romidepsin, belinostat, and panobinostat. Vorinostat,
romidepsin and belinostat are approved for the treatment of
patients with cutaneous T-cell lymphoma (CTCL). Panobinostat
is approved for the treatment of patients with multiple myeloma.
However, HDAC inhibitors modulate EMT-related factors
expression in cancer-type dependent manner. The effect of
HDAC inhibitors such as Trichostatin A (TSA) and Valproic
acid (VPA) on EMT seem controversial, with both pro-invasive
and anti-invasive activities having been described. Some studies
reveal that treatment with TSA reverses EMT via suppressing
Slug in breast cancer, colorectal and prostate cancer cells (Wang
et al., 2015; Wang X. et al., 2020). VPA inhibits glioma stem cells
invasion through Snail and Twist1 downregulation and
E-Cadherin re-localization (Riva et al., 2018), and blocks EMT
in prostate carcinoma cells via repression and mono-
ubiquitination of SMAD4 (Lan et al., 2016). Conversely, other
reports demonstrated that TSA treatment with esophageal
squamous cell carcinoma cells increases acetylation of RelA,
thereby enhancing Slug expression which in turn induces
EMT (Huang et al., 2020). In hepatocellular carcinoma cells,
TSA/VA significantly induces the EMT phenotype with
decreased E-cadherin, increases N-cadherin, vimentin, Snail
and Twist1, and an enhanced capacity for cell migration and
invasion (Yang et al., 2018). Similarly, HDAC inhibitors induce
mesenchymal transition of the colon carcinoma cells, especially in
the presence of TGF-β1 (Ji et al., 2015). They enhance invasion of
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human melanoma cells via upregulation of N-cadherin and
inhibition of RhoA activity (Díaz-Núñez et al., 2016), and
these inhibitors upregulate Snail through AKT/GSK-3β signals
and post-transcriptional modification to promote EMT in
colorectal cancer cells (Feng et al., 2015). Thus, the application
of HDAC inhibitors for chemotherapeutic intervention requires
careful caution. HDAC inhibitors represent the first successful
anti-epigenetic therapy, so far, only four inhibitors have been
approved by FDA. However, HDAC inhibitors emerge as a
promising class of drug, particularly in combination with
other agents.
Acetylation Readers
By acting as epigenetic markers, histone acetylation also provides
binding sites for acetyl reader proteins such as the bromodomain-
containing proteins (BRDs). BRDs binds to ε-N-aminoacetyl
groups of nucleosomal histone lysine and recruits histone
modifiers and transcriptional/remodeling factors to gene
promoters, thereby upregulating or repressing gene expression
in response to different biological signals. Ever increasing studies
in different cancer cells have demonstrated the contribution of
BRDs to cancer progression, reinforcing the therapeutic value of
acetyl reader proteins (Belkina and Denis, 2012).
Recently, we found that acetylation of Twist1 by Tip60
acetyltransferase recruits BRD4 to the promoter and enhancer
ofWNT5A to modulate its expression. Pharmacologic inhibition of
the Twist1-BRD4 interaction with JQ1 or MS417 reduces WNT5A
expression and suppresses cell invasion, CSC-like properties, and
tumorigenicity in basal-like breast cancer cell lines (Shi et al., 2014).
Similarly, the acetylated SPZ1-Twist1 complex recruits BRD4 to
upregulate expression of vascular endothelial growth factor, thus
enhancing RNA-Pol II-dependent transcription and inducing
metastasis (Wang L.-T. et al., 2019). Moreover, inhibition of
BRD4 decreases Snail expression by diminishing the protein
kinase D1 mediated proteasome degradation pathway. BRD4
inhibition also suppresses the expression of Gli1 which is
required for transcriptional activation of Snail, indicating that
BRD4 controls malignancy of breast cancer cells via both
transcriptional and post-translational regulation of Snail (Lu
et al., 2020). In renal cell carcinomas, inhibition of BRD4 by
genetic knockdown or JQ1 prevents cell proliferation and EMT,
and induces NF-κB-NLRP3-Caspase 1-dependent pyroptosis,
providing evidence for BRD4 being a potential target and JQ1
as a therapeutic agent for renal cell carcinomas (Tan et al., 2020).
Interestingly, we discovered that JQ1 has different effects on cell
migration in AR-positive and AR-negative prostate cancer cells,
which indicates that the function of BRD4 is cellular-context
dependent (Wang J. et al., 2020). Owing to the experimental
tractability and high potentials to bind small molecules, a
variety of BRD inhibitors have been discovered that display
good anti-inflammatory and anticancer activities. Several BRD
inhibitors including OTX015, BET-d246, ABBV-075 have since
advanced to early clinical trials to determinate safety, tolerability,
and efficacy as a monotherapy and in combination with other
agents (Mohammad et al., 2019). A major problem for the clinical
translation of BRD inhibitors has been the relative immature
understanding of BRD cellular functions and their relevance in
disease; increasing validation and optimizing clinical
comprehension is therefore a promising scenario for advanced
cancer therapy (Cochran et al., 2019).
Methylation
Histone lysine methylation is catalyzed by lysine
methyltransferases (KMTs), which use S-adenosylmethionine
as the methyl donor to align methyl groups to lysine residues.
Unlike acetylation, histone methylation keep the charge of the
histone protein and lysine residues can be monomethylated,
dimethylated, or trimethylated, respectively. Histone
methylation directly recruit or inhibit the recruitment of
histone-binding proteins. For instance, H3K9 and H3K27
methylation are usually associated with transcriptional
activation, while H3K79 is often linked with gene repression.
Among all these KMTs, development of inhibitors of EZH2
(Enhancer of zeste homolog 2) and DOT1L (Disruptor of
telomeric silencing-1-like) have advanced to clinical trials.
EZH2, the catalytic subunit of the Polycomb Repressive
Complex 2 (PRC2), promotes gene silencing by catalyzing
mono/di/tri-methylation of H3K27, a major transcription
repressive modification. Many studies show that EZH2
mediates transcriptional silencing of E-cadherin by
trimethylation of H3K27, which establishes a functional link
between dysregulation of EZH2 and aberrant modulation of
EMT programs (Cao et al., 2008; Herranz et al., 2008).
Different types of EZH2 inhibitors have been developed, and a
number of drugs are ongoing in clinical trials for different cancer
types. DZNep, the first EZH2 inhibitor, globally inhibits histone
methylation but is not specific to EZH2 (Miranda et al., 2009).
Tazemetostat (Tazverik
™
) is a selective and orally bioavailable
EZH2 inhibitor. In January 2020, it was approved by FDA for
adults and pediatric patients aged 16 years and older with
metastatic or locally advanced epithelioid sarcoma not eligible
for complete resection (Duan et al., 2020). Recently, many new
drugs targeting EZH2 are under development and evaluation in
clinical trials including combinational treatment (Duan et al.,
2020). Combining EZH2 inhibitors with other treatments such as
immune therapy, conventional chemotherapy, and targeted
therapy might have a synergic effect on tumor metastasis.
DOT1L catalyzes the methylation of an active transcription
mark histone H3K79, which is crucial for tumor development
(Okada et al., 2005). During reprogramming of embryonic stem
cells, several EMT-TFs associated with DOT1L are modified by
H3K79me (Onder et al., 2012). In breast cancers, DOT1L forms a
transcriptionally active complex with c-Myc and p300 to facilitate
H3K79 methylation and acetylation in the promoter regions of
EMT-TFs and enhance their de-repression, consequently
promoting EMT-induced CSC properties (Cho et al., 2015).
EPZ004777, the first reported DOT1L inhibitor, inhibits self-
renewal and metastatic potential of breast cancer (Wong et al.,
2015). In addition, treatment with a highly selective inhibitor
EPZ5676 or small interfering RNA against DOT1L reduces
expression of Snail and Twist1, and inhibits TGF-β1 and
serum-induced activation of renal interstitial fibroblasts and
EMT (Liu et al., 2019). Targeting DOT1L by a novel
psammaplin A analog augments expression of E-cadherin and
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suppresses N-cadherin, ZEB1, and vimentin expression and
inhibits growth and metastasis of triple-negative breast cancers
(Byun et al., 2019). These studies provide evidence that targeting
DOT1L-mediated H3K79 methylation may be a promising
strategy for the treatment of cancer.
Moreover, many other KMTs such as G9a have been
characterized with respect of EMT. G9a is a major KMT
responsible for the transcriptionally repressive modification of
H3K9. G9a is preferentially expressed in aggressive lung cancer
cells and its elevated expression correlates with poor prognosis.
G9a represses a cell adhesion molecule EPCAM by catalyzing
H3K9me2 on its promoter to stimulate EMT and cancer
metastasis of lung cancer cells (Chen et al., 2010). In breast
cancer cells, G9a is recruited to the E-cadherin promoter for
transcription silencing by interaction with Snail. Inhibiting G9a
reduces promoter H3K9me2 as well as DNA methylation and
further abrogates EMT and tumor metastasis (Dong et al., 2012).
A similar mechanism was also reported in head and neck
squamous cell carcinoma (Liu et al., 2015). In recent years,
many potent G9a inhibitors have been discovered based on
their binding modes: 1) substrate competitive inhibitors, such
as UN0638; 2) the SAM (S-adenosyl -methionine) cofactor
competitive inhibitors; 3) mechanism remains unclear (Cao
et al., 2019). BIX01294 was the first small molecular G9a
inhibitor identified by high-through screening in 2007
(Kubicek et al., 2007). Treatment with BIX01294 not only
inhibits cell proliferation but also affects breast cancer
migration (Kim et al., 2018; Chae et al., 2019). The recently
reported discovery of UNC0638, an inhibitor of G9a and GLP (a
KMT which shares similar functional domains to and forms a
heterodimer with G9a) has excellent potency and selectivity.
UNC0638 treatment decreases global H3K9me2 levels and
reduces H3K9me2 at promoters of G9a-regulated endogenous
genes (Pan et al., 2015). In addition, UNC0638 activates
E-cadherin expression and reverses EMT, thereby inhibiting
tumor growth in pancreatic cancer cells (Vedadi et al., 2011).
To date, there are no G9a inhibitors in clinical trials.
Demethylation
Histone lysine-specific demethylase 1 (LSD1) functions as an
epigenetic regulator by removing methyl groups from the
transcription-activating H3K4 or the repressive H3K9 through
an amine oxidase reaction (Shi et al., 2004; Metzger et al., 2005).
Overexpression of LSD1 has been detected in a variety of tumors
and is associated with metastasis and drug resistance, therefore
LSD1 is regarded as a biomarker of poor prognosis. LSD1 often
takes part in different chromatin-remodeling protein complexes
and targets distinct proteins that regulate tumor progression. We
found that the amine oxidase domain of LSD1 interacts with the
SNAG domain of Snail (Lin et al., 2010). SNAG, similar to the
histone H3 tail, acts as a molecular hook to recruit LSD1 and form
the Snail1-LSD1-CoREST complex to repress E-cadherin
expression and enhance cell migration (Lin et al., 2010).
Another study indicated that Snail recruits LSD1 on epithelial
gene promoters for H3K4 me2 demethylation, thereby silencing
their expression and promoting EMT (Lin et al., 2010). By
contrast, LSD1 can inhibit cellular invasiveness and exerts a
metastasis inhibition function by acting as an integral
component of the Mi-2/NuRD complex (Wang et al., 2009),
or forming a complex with Sin3a to maintain the epithelial states
(Yang et al., 2018). These contradictory findings indicate that
LSD1 regulates EMT through diverse mechanisms possibly
because of multiple histone lysine sites it can modify when
combined with different complexes.
Specific modulation of LSD1 activity with inhibitors has been
a promising therapeutic approach. Multiple LSD1 inhibitors
have been discovered including irreversible and reversible
inhibitors. For instance, treatment with Parnate, an
enzymatic inhibitor of LSD1, or TAT-SNAG, a cell-
permeable peptide corresponding to the SNAG domain of
Slug, blocks the Snail/Slug-LSD1 interaction and suppresses
the motility and invasiveness of cancer cells of different
origins and genetic background (Ferrari-Amorotti et al.,
2013). Pretreatment of cancer cells with the LSD1/2 inhibitor
Tranylcypromine (TCP), an irreversible inhibitor, attenuates
Snail-mediated of epithelial gene downregulation and
upregulation of mesenchymal marker genes. Combined
treatment with TCP and TSA completely abrogates EMT
(Javaid et al., 2013). SP-2509 is a highly potent, reversible,
and non-competitive LSD1 inhibitor which was discovered
through high-throughput virtual screening (Sorna et al.,
2013). Treatment of SP-2509 suppressed prostate cancer
migration, and metastasis independent of AR expression
(Wang et al., 2020). For now, several LSD1 inhibitors
including TCP, ORY-1001, GSK2879552, IMG-7289,
INCB059872, and ORY-2001(Vafidemstat) are being tested in
clinical trials targeting anti-tumor traits, alone or in combined
treatment for cancer therapy (Fang et al., 2019). Therefore,
determination of their effects on EMT traits represents another
potential validation of novel epigenetic drugs.
EPITHELIAL-MESENCHYMAL TRANSITION
AND NON-CODING RNA: MICRORNA AND
LONG NON-CODING RNA
Over recent years, more and more non-coding RNAs (ncRNAs)
have been identified as crucial regulators for a variety of cellular
functions including tumor progression and EMT (Anastasiadou
et al., 2018). As a result, much attention has been paid on using
ncRNAs as potential targets for tumor treatment including for
EMT interference (Matsui and Corey, 2017). MicroRNAs
(miRNAs) are small endogenous ncRNAs consisting of about
19–25 nucleotides that play important roles in gene expression,
and underlie physiological and pathological processes (Bracken
et al., 2016). MiRNAs can promote or suppress EMT by
modulating the expression of EMT-TFs or its regulatory
elements. Therefore, miRNA therapeutics could be achieved by
either administration of miRNA mimics or anti-miRNAs.
MiRNA mimics are synthetic double-stranded small RNA
molecules that have the same sequences as the corresponding
miRNAs and can restore their normal expression and function.
By contrast, anti-miRNAs have complementary sequences so as
to bind to target miRNAs and block their function.
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MicroRNA
miR-21 is an oncogenic miRNA with anti-apoptotic roles that is
overexpressed in tumors compared with normal tissues, and a
potent inducer of EMT (Pan et al., 2010). Recent reports revealed
that miR-21 governs lung cancer cell progression and EMT
through regulation of PTEN/Akt/GSK3β signaling cascade (Dai
et al., 2019). Treatment with a specific inhibitor to miR-21,
AC1MMYR2, blocks procession of pre- miR-21 to mature
miR-21. This blockade causes EMT reversal and suppresses
tumor growth and invasion, partly through upregulation of
miR-21 targets as demonstrated in epithelial tumor cells and
orthotopic nude mouse models (Shi et al., 2013). A selective
peptide identified by phage display downregulates miR-21
expression through binding to pre-miR-21 which hinders
Dicer processing. By antagonizing miR-21 function, this
peptide is able to increase the expression of target proteins
that increase apoptosis and suppress cell proliferation, invasion
and migration (Bose et al., 2015). Moreover, treatment of
sophocarpine, a naturally occurring tetracyclic quinolizidine
alkaloid with promising therapeutic properties, blocks Dicer-
mediated miR-21 maturation and leads to EMT reversal and
growth inhibition in head and neck squamous cell carcinoma (Liu
et al., 2017). Similarly, another natural product, butylcycloheptyl
prodiginine also binds and inhibits Dicer-mediated processing of
pre-miR-21 and selectively arrests growth of colon cancer cells
(Matarlo et al., 2019).
Unlike aberrant upregulation of miR-21, expressions of miR-
34 and miR-200 are repressed in a broad range of cancers. A
dynamic model of the core EMT regulatory circuit was recently
proposed based on two mutually inhibiting microRNA-TF
loops, miR-34 (a,b,c)/Snail and miR-200/ZEB (Lu et al., 2013;
Jia et al., 2019). Snail and ZEB repress the transcription of miR-
34a/b/c and miR-200, respectively, while miR-34a/b/c and miR-
200 bind with the corresponding mRNAs to inhibit protein
levels of Snail and ZEB, by blocking their translation and/or
enhancing their degradation (Park et al., 2008; Schliekelman
et al., 2011; Siemens et al., 2011). Treatment with MRX34, a
miR-34a mimic encapsulated in lipid nanoparticles, leads to
significant tumor regression in the aggressive Kras:Trp53
NSCLC mouse model (Wiggins et al., 2010). Combination of
miR-34a with another repressor miRNA let-7 using the same
lipid particles, individually or in combination, results in
synergistic potentiation of the anti-proliferative effects of
erlotinib, the epidermal growth factor receptor inhibitor
(Stahlhut and Slack, 2015). However, despite its promise, in
several preclinical studies of different cancers, MRX34 clinical
phase I trials have been halted because of immune-related
serious adverse events. MiR-200 is another miRNA that has
been targeted in preclinical studies. It was demonstrated that
delivery of miR-200 mimics using DOPC lipid nanoparticles
markedly reduces metastasis and angiogenesis and induces
vascular normalization in several types of cancer (Pecot
et al., 2013). In an orthotopic mouse model of lung cancer,
treatment of tumors with miR-200c mimics enhances
radiosensitivity, suggesting combination of miR-200 with
radiation represents a therapeutic strategy in the future
(Cortez et al., 2014). Although these studies have not
examined directly whether therapeutic delivery of miR-200
results in EMT inhibition or reversal, a recent study revealed
that nanoparticle delivery of miR-506, a miRNA that prevents
TGFβ-induced EMT by targeting Slug, effectively suppresses
tumor growth and blocks EMT in two ovarian cancer models
(Yang et al., 2013). Future studies are needed for development of
novel miRNA inhibitors and mimics with efficient delivery
systems and to validate their clinical value relevant to EMT
and tumor progression.
LncRNA
Long ncRNAs (lncRNAs) belong to a class of ncRNA that are
longer than 200 bp and have weak protein-coding potential.
Many studies show that lncRNAs have significant roles in
diverse biologic processes that affect gene expression at
multiple levels, from gene transcription to protein expression;
hundreds have been identified to be aberrantly expressed in
human cancers (Anastasiadou et al., 2018; Slack and
Chinnaiyan, 2019). In particular, an increasing number of
lncRNAs are reported to be implicated in tumor progression
and metastasis (Slack and Chinnaiyan, 2019). A major
mechanism by which lncRNAs regulate EMT is by
epigenetically silencing EMT-related genes such as E-cadherin
via recruitment of transcriptional repressors like PRC2 (Lin et al.,
2018). Alternatively, lncRNAs contribute to the modulation of
EMT by acting as competing endogenous RNAs (ceRNAs) for
EMT-associated miRNAs and impeding the interaction of these
miRNAs with their target molecules in a stoichiometric manner
(Wang L. et al., 2019; Fang et al., 2020). In terms of the canonical
miR-200/ZEB double negative feedback loops which are critical
to the induction of EMT, a number of lncRNA including
lncRNA-ATB, H19 and HULC upregulate ZEB1/2 by
competitively binding the miR-200 family and induce EMT
(Yuan et al., 2014; Liang et al., 2015; Expósito-Villén et al.,
2018; Liu et al., 2019; Ashrafizadeh et al., 2020). Likewise,
transforming growth factor beta-induced (TGFBI) functions as
a ceRNA for miR-21 and leads to de-repression of its endogenous
targets FOXP1, a potent transcriptional inducer of EMT in A549
cells (Liu et al., 2019).
LncRNAs can be therapeutically targeted by a variety of
approaches such as RNA interference, antisense
oligonucleotides (ASO)-based therapy, lncRNA mimics and
small molecule inhibitors. Several studies showed the success
of LncRNA treatment in cancer therapy. For example, BC-819, a
double stranded DNA plasmid that targets the expression of
diphtheria-toxin gene under the control of H19 regulatory
sequence, has been tested in clinical phase 2b trails in different
cancers with promising therapeutic benefits (Hanna et al., 2012;
Gofrit et al., 2014; Lavie et al., 2017). Metastasis associated lung
adenocarcinoma transcript 1 (MALAT1) is extremely abundant
in many human cell types and highly conserved across
mammalian species (Sun and Ma, 2019). Subcutaneous
injection of MALAT1-targeting ASO in a mouse model of
metastatic luminal B breast cancer resulted in the formation of
cystic and non-metastatic tumors (Arun et al., 2016). In vivo
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injection of MALAT1 ASOs also successfully decreased the
expression of MALAT1 and suppressed lung cancer
progression, which suggests that targeting MALAT1 in lung
cancer patients is a potential and promising clinical therapy
(Gutschner et al., 2013). Due to its high potency, RNA
technology provides immense therapeutic promise. The
development of new technologies will help to bring lncRNA-
based therapies closer to the clinic (Khorkova and Wahlestedt,
2017).
DISCUSSIONS
Over the past a few years, EMT research has experienced an
explosive growth and emerged as a key event for evasion to
various types of cancer therapy (Boumahdi and de Sauvage,
2020). Along with ever broadening comprehension of the
mechanisms that control this phenotypic shift, its close
connection to CSCs, drug resistance and other properties
associated with tumor invasion and metastasis, there is
rising interests to exploit EMT as a potential therapeutic
target (Figure 1). The development of specific drugs against
EMT is continuously increasing (Voon et al., 2017). Because of
the reversibility of the epigenetic marks and the enzymatic
nature of the regulators, EMT as a reversible and transient
process, with intimate connection between EMT-TFs and
chromatin-remodeling enzymes, targeting the epigenetic
enzymes to reverse the EMT process is an efficient and
promising approach. However, the clinical advancement for
targeted anti-EMT therapy is still a field in its infancy (Brabletz
et al., 2018), and there are only a few studies based on
treatments that directly target EMT (Santamaria et al.,
2017). Several problems need to be overcome to treat the
EMT more efficiently and specifically by epigenetic
inhibitors: First, the mechanisms responsible for the
initiation, maintenance and alteration of the EMT schedule
remain largely unknown and need further investigation;
Second, the epigenetic regulators that contribute to the
spectrum of EMT, particular during the intermediate states
must be defined; Third, do the EMT-TF domains directly or
indirectly interact with epigenetic enzymes; would disruption
between EMT-TFs and epigenetic regulators reverse EMT-
related properties? Fourth, epigenetic enzymes have variability
based on the cellular context, that is, they can have an opposite
function by formation distinct complexes in different cancers;
therefore, how can we formulate EMT treatments with
precision using an epigenetic inhibitor? Finally, how do
EMT-TFs and the epigenetic network functionally cooperate
with each other? How do they specifically intertwine to modify
the EMT?
In all, additional knowledge of the EMT-TF epigenetic
network will provide new efficient and specific avenues to
enhance the clinical use of “epigendrug” to tackle EMT in
cancer in the future.
FIGURE 1 | Epigenetic modifications and related key inhibitors involved in Epithelial-Mesenchymal Transition (EMT). Epigenetic regulations including DNA
methylation, histone modification and non-coding RNAs are integral to EMT which contribute to tumor metastasis, cancer stem cell properties, drug resistance and
recurrence. Epigenetic drugs are illustrated to inhibit EMT including histone deacetylase (HDAC) inhibitor, histone acetylase inhibitor, acetylation reader inhibitor, histone
methyltransferase inhibitor, histone demethyltransferase inhibitor, DNA methyltransferase (DNMT) inhibitor, and non-coding RNA activation and repression.
LncRNA, Long non-coding RNAs; MALAT1, Metastasis Associated Lung Adenocarcinoma Transcript 1; ASO, antisense oligonucleotides; BRD4, Bromodomain-
containing protein 4; LSD1, Lysine-specific demethylase 1; EZH2, Enhancer of zeste homolog 2; DOT1L, DOT1 Like Histone Lysine Methyltransferase.
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